Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Pfizer Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.47B), while Pfizer Inc trades at $29.55 (market cap $166.49B). The key difference: Pfizer Inc is far larger — about 19.7× Hinge Health Inc. Class A Common Stock's market cap, and Pfizer Inc pays a 5.89% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Pfizer Inc for 158 Days on average.
| HNGE | PFE | |
|---|---|---|
Market Cap | $8.47B | $166.49B |
Volume | 1,624,526 | 39,330,520 |
Sector | Health | Health |
52-Week High | $105.14 | $29.21 |
52-Week Low | $31.17 | $23.67 |
Typical Hold Time | 0 Days | 158 Days |
Enterprise Value | $8.09B | $217.98B |
Dividend Yield | — | 5.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Pfizer (PFE) trades at $28.37, down slightly by 0.11% on the day, with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on obesity and oncology pipeline developments, positioning for a catalyst-rich 2026.
Pfizer presents a mixed outlook with stable revenue around $63B but declining net income projections for 2026. The stock trades near analyst consensus target of $29.17, offering modest upside potential. Key risks include patent cliffs and competitive pressures, while the dividend yield and pipeline progress provide defensive appeal for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
